Antibody capable of binding to thymic stromal lymphopoietin and use thereof
US12404323B2 · kind B2 · utility
0Cited by
1References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 3, 2020 |
| Grant date | Sep 2, 2025 |
| Priority date | — |
| Expiry date | Mar 10, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are an antibody capable of binding to thymic stromal lymphopoietin and the use thereof. Disclosed are an anti-TSLP antibody, comprising a murine antibody, chimeric antibody and humanized antibody of the light chain and heavy chain variable regions of the anti-TSLP antibody and antigen-binding fragments thereof, or a pharmaceutically acceptable salt or solvent compound thereof, and the use thereof as a medicament for treating asthma, especially the use thereof in the preparation of a drug for treating TSLP-positive diseases or conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.